TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

Ladenburg raised the firm’s price target on TG Therapeutics (TGTX) to $45 from $43 and keeps a Buy rating on the shares. The company reported strong Briumvi revenue in Q3, the analyst tells investors ...

It's been a good week for TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders, because the company has just released ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

Third Quarter 2024 Results Key Financial Results Revenue: US$83.9m (down 49% from ...

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET ...